Introduction: Breast cancer is the most common cause of cancer death among women. Estrogen Receptor (ER), Progesterone Receptor (PR) and human epidermal growth factor receptor 2 (Her-2/ neu) status are used as an important prognostic marker for breast cancer.
Introduction
Of the 10 million new cancer cases diagnosed each year, 4.7 million are in the more developed countries and nearly 5.5 million in the less developed countries. The number of cancer cases in India is increasing due to increasing population, increase in the proportion of older people, changing patterns of lifestyles. Cancer is currently the cause of 12% of deaths worldwide. In approximately 20 years, the number of cancer deaths annually will increase from 6 million to 20 million. However, the impact of cancer is far greater than the incidence and mortality would suggest, including impact on health care costs 1 .
Breast cancer in women is a major health burden. It is the most common cause of cancer deaths among women in both high resource and low resource countries 2 . Recent global cancer statistics indicate that breast cancer incidence is rising at a faster rate in populations of developing countries 2, 3 . The incidence of breast cancer in Bangladesh seems to be very high. All the patients were managed by surgery followed by chemotherapy and hormone therapy. ER positive patients were treated by Tamoxifen and Her-2/nu overexpression cases were treated by herceptin. All the patients were followed up every 6 months up to maximum 1 and half year. The results were analyzed using the statistical software SPSS for windows, version 11. Association of clinicopathological parameters with ER and Her-2 state were analyzed using chi-square test. Statistical significance was defined as p<0.05.
Results
A total 100 breast carcinoma cases diagnosed at histopathology department of a tertiary level hospital at Dhaka, Bangladesh were included in the study. All the patients were female ranged from 22 yrs to 80 yrs. Mean age was 45.64 yrs. Forty two (42%) patients were of less than 40 yrs and 58 (58%) were more than 40 yrs. Of the 100 cases included in this study 93 were diagnosed as infiltrating duct cell carcinoma, 03 were infiltrating lobular carcinoma, 02 were mucinous carcinoma, 01 medullary carcinoma and 01 was metaplastic carcinoma. The size of the tumour ranged from 1.5 cm to 10 cm with a mean size of 4.45 cm. The tumour size < 2 cm were 11, 2-5 cm were 60 (60%) and > 5 cm were 29. Among 93 infiltrating duct cell carcinoma cases, 11 (11.83%) were of grade 1, maximum that is 43 (46.24%) were of grade 2 and 39 (41.93%) were of grade 3. Among 100 cases mastectomy specimen with axillary tissue were received in 62 cases. Rests 38 were received as lumpectomy specimen. Among these 62 mastectomy cases lymph node involvement were assessed and metastatic deposits were found in 45 (72.58%) cases and 17(27.42%) were negative. Two immunohistochemical parameters ER and Her-2/neu were available for all 100 cases. For ER, quick score was '0' to '2' that was found in 62 (62%) cases and were considered as ER negative. Quick score for ER was between 3 to 8 in 38 (38%) cases and they were considered as positive ( Figure-1 and 2).
Fig-1:
Immunohistochemistry for ER in ductal carcinoma, score-6/8.
Fig-2:
Immunohistochemistry for ER in lobular carcinoma, score-7/8.
Details of clinicopathological features are described in Table-I . Her-2 borderline cases were not confirmed by her-2 FISH due to it's unavailability in Bangladesh. Among 100 cases 03 were both ER and Her-2 positive, 25 were ER positive but Her-2 negative, 10 were ER positive but Her-2 borderline, 27 were ER negative but Her-2 positive, 23 were ER negative and Her-2 negative, 12 were ER negative but Her-2 borderline.
Table-IV: ER and Her-2 state of study population (n=100).
Study populations were managed following standard protocol by oncologists. After surgery all the patients were treated by chemotherapy followed by radiotherapy. After that the patients were given immunotherapy depending of their ER positivity and Her-2 expression and the patients were followed up from 6 months to maximum 2 yrs. All patients survived the follow up duration. So the overall survivality (OS) is 100%. 33 . In this study, the difference in receptor status with nonductal carcinoma is probably due to very small number of non ductal carcinoma cases in the series. In this study we could follow up the cases for maximum 18 months. Over all survivality was 100%. But disease free survival could not be assessed due to lack of regular follow of the patients. In a study in Singapore General Hospital 5.2% deaths have documented among follow up of 290 breast cancer patients 24 .
Conclusion
The prevalence of hormone receptor positive breast cancer is less in Asian women including women of Bangladesh which has been proved by this study too. Though the present study is a short series study but possibly the first one of this kind in this country. In contrast to western countries this study revealed more rate of Her-2/neu over expression which is similar to other studies of Asian countries. Her-2/neu overexpression is related with other poor prognostic parameters like high grade and histological type. For planning the treatment protocol of the patients' hormone receptor studies as well as Her-2/neu study are almost mandatory prerequisites.
